



Overview of the REMS Integration Initiative December 4th 2017

Center for Drug Evaluation and Research (CDER)



Purpose

- To introduce the new REMS document template, and...
- To discuss work completed under the REMS Integration Initiative

Agenda



- 1. Introduction & Background (Aaron Sherman)
- 2. The new REMS document template (Gita Toyserkani and Suzanne Robottom)
- 3. **REMS@FDA** website update (Amy Ramanadham)
- 4. REMS SPL update (Adam Kroetsch)

What is a REMS?



- <u>R</u>isk <u>Evaluation and Mitigation Strategy</u>
- A required risk management plan that uses risk minimization strategies beyond professional labeling to ensure that the benefits of the drug outweigh its risks
- Authority given under the FDA Amendments Act (FDAAA) of 2007
 - Section 505-1 of the FD&C Act
- FDA can require a REMS:
 - Before approval if FDA determines a REMS is necessary to ensure the benefits of the drug outweigh the risks
 - After approval if FDA becomes aware of new safety information and determines that a REMS is necessary to ensure the benefits of the drug outweigh the risks
- There are currently 76 approved REMS

Key Components of the REMS Integration Initiative



- Stakeholder outreach to evaluate and improve REMS
- Standardization and integration of REMS into existing healthcare practices, and reducing associated burden
- Implementation of REMS commitments included in the 5th reauthorization of the Prescription Drug User Fee Act (PDUFA)¹
 - Guidance development
 - 4 priority projects to address specific areas of improvement

Stakeholder Engagement



Date	Activity	
March 8, 2013	PDUFA Stakeholders Meeting	
March – June 2013	15 Stakeholder Listening Sessions — Experience Implementing ETASU REMS	
May 16, 2013	Drug Safety Board Meeting	
May 23, 2013	Trends Emerging in Risk Management (TERM) Meeting	
July 25-26, 2013	Public Meeting: REMS Standardization and Evaluation	
Sept. 25, 2013	Strengthening REMS Through Systematic Analysis, Standardized Design, and Evidence- Based Assessment (Brookings)	
Sept. 2014	Report: Standardizing and Evaluating REMS (<u>link</u>)	
Feb. 6 / May 6, 2015	NCPDP Workgroup Meeting and Annual Conference	
Feb. 9, 2015	HL7 SPL Tech Team Meeting	
May 18, 2015	Incorporating continuing education into single-drug REMS: Exploring the challenges and opportunities (Brookings)	
July 25, 2015 / April 14, 2016	Expert Workshop – Providing Patient Benefit Risk Information (Brookings)	
Oct. 5-6, 2015	Public Meeting: Understanding and Evaluating REMS Impact on the Health Care Delivery System and Patient Access	
Dec. 2015 – May 2016	REMS SPL Pilot with 9 companies to test & refine the REMS data model/terminology	







Stakeholder Feedback: Key Themes

Stakeholders told us that:

- REMS materials and requirements are not communicated clearly and consistently
- Specific activities and requirements are not always clearly outlined
- Stakeholders reported spending excessive time trying to locate, understand, and comply with different REMS requirements

Guidances



- Use of a Drug Master File [DMF] for Shared System REMS Submissions (<u>link</u>)
- Format and Content of a REMS Document (link)
- Providing Regulatory Submissions in Electronic Format – Content of the REMS Document Using Structured Product Labeling (<u>link</u>)
- FDA's Application of Statutory Factors in Determining When a REMS Is Necessary (<u>link</u>)
- *REMS: Modifications and Revisions* (<u>link</u>)

REMS Priority Projects

The following priority projects were selected as part of a PDUFA V commitment and completed under the REMS Integration Initiative.

	Projects Selected	Deliverable
1	Providing Patient <i>Benefit/Risk</i> Information by Improving Tools for Prescriber-to-Patient Counseling	A Framework for Benefit-Risk Counseling to Patients about Drugs with a REMS (<u>link</u>)
2	Prescriber Education—REMS and Continuing Education (CE) for Health Care Providers	A report on the feasibility of REMS-related CE including a description of potential models for REMS-related CE development and delivery (<u>link</u>)
3	Standardizing REMS Information for Inclusion into <i>Pharmacy</i> <i>Systems</i> Using Structured Product Labeling (SPL)	A revised SPL implementation guide describing how to make structured REMS information available to patients and healthcare providers.
4	Providing a Central Source of REMS Information for <i>Practice</i> <i>Settings</i>	An enhanced FDA REMS Website (<u>REMS@FDA</u>)

The "4 W's" of REMS



This is the key organizational principle serving as the foundation for how REMS information is organized in the new REMS document template, in SPL format, and on the REMS@FDA website.

"W"	Description	Examples
"Who"	The participant who must meet the REMS requirement	prescriber, dispenser, health care setting
"When"	A particular "stage" in the treatment or medication use process around which REMS activities needs to occur	certification, prescribing, dispensing, administration
"What"	a clinical or administrative activity that must be performed as part of the REMS	counseling a patient, completing an enrollment form, lab testing
"With What"	Approved REMS material with which the requirement is carried out	enrollment form, medication guide, educational pamphlet

Agenda



- 1. Introduction & Background (Aaron Sherman)
- 2. The new REMS document template (Gita Toyserkani and Suzanne Robottom)
- 3. **REMS@FDA** website update (Amy Ramanadham)
- 4. REMS SPL update (Adam Kroetsch)

Overview



- History of the REMS Document
- Development of the New REMS Document Template
- Overview of the New REMS Document Template
- Submitting a REMS Document



HISTORY OF THE REMS DOCUMENT



What does FDA approve?

REMS Document

Risk Evaluation and Mitigation Strategy (REMS) Document Welipax (welimab) REMS Program

I. Administrative Information

Application Number: BLA 123456 Applicant: EarmEa, Inc Initial REMS Approval: 01/2017 Most Recent REMS Update: 12/2017

II. REMS Goal

The goal of the <u>Welgas</u> REMS Program is to mitigate the observed risk of holiday stress associated with <u>Welgas</u> by:

- Ensuring that prescribers are educated about the risk of holiday stress and the need to coursel patients about this risk.
- Ensuring that patients are informed about the thic of holday stress observed with Weilpac therapy and the red to seek medical attention for new meat or vorsening depression, anxiety, or other mod changes

III. REMS Requirements


EarmEa must ensure that health care providers, patients, pharmacies, and wholesalers/distributors comply with the following requirements:

1. Health care providers who prescribe Welipax must:

To become certified to prescribe	1. Review the drug's Prescribing Information 2. Review the Prescriber Education Program.	
	Review the Presciber Education Program. Enroll in the REVS by completing the Presciber Enrollment Firm and submitting it to the REVS Program.	
Before treatment initiation (first dose)	 Counsel the patient that holiday stress occurs with patients treated with <u>Weipays</u>, to be aware of symptoms and steps to take if symptoms occur. 	
	5. Provide the patient with the Patient Wallet Card	
	 Enroll the patient by completing and submitting the Patient-Prescriber Agreement Form to the REMS Program. Retain a copy in the patient's record. 	
At all times	 Inform FarmFa if a patient is no longer under your care or has discontinued treatment. 	



REMS Materials



REMS Document



- The 'face' of the REMS
 - Introduced with the first approved REMS in 2008
- Purpose of the REMS document
 - Establishes the REMS requirements for applicants
 - Communicates the REMS requirements for stakeholders (e.g., prescribers, pharmacists, healthcare administrators, distributors, patients)
- The only document that captures the requirements for all applicable stakeholders
- A REMS Document 'Template' was included in 2009 as part of draft guidance for Industry *Format and Content of REMS, REMS Assessments, and Proposed REMS Modifications*

Old REMS Document Template



Initial REMS Approval: XX/XXXX Most Recent Modification: XX/XXXX

APPENDIX A: REMS TEMPLATE

If you are not proposing to include one of the listed elements, include a statement that the element is not necessary.

Application number TRADE NAME (DRUG NAME)

Class of Product as per label

Applicant name

Address

Contact Information

RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL(S):

List the goals and objectives of the REMS.

II. REMS ELEMENTS:

A. Medication Guide or PPI

If a Medication Guide is included in the proposed REMS, include the following:

A Medication Guide will be dispensed with each [drug name] prescription. [Describe in detail how you will comply with 21 CFR 208.24.]

B. Communication Plan

If a Communication Plan is included in the proposed REMS, include the following:

[Applicant] will implement a communication plan to healthcare providers to support implementation of this REMS.

List elements of communication plan. Include a description of the intended audience, including the types and specialties of healthcare providers to which the materials will be directed. Include a schedule for when and how materials will be distributed. Append the printed material and web shots to the REMS Document.

C. Elements To Assure Safe Use

If one or more Elements to Ensure Safe Use are included in the proposed REMS, include the following:

List elements to assure safe use of Section 505-1(f)(3)(A-F) included in this REMS. Elements to assure safe use may, to mitigate a specific serious risk listed in the labeling, require that:

A. Healthcare providers who prescribe [drug name] have particular training or experience, or are specially certified. Append any enrollment forms and relevant attestations/certifications to the REMS;

 Pharmacies, practitioners, or healthcare settings that dispense [drug name] are specially certified. Append any enrollment forms and relevant attestations/certifications to the REMS;

- C. [Drug name] may be dispensed to patients only in certain healthcare settings (e.g., hospitals);
- D. [Drug name] may be dispensed to patients with documentation of safe-use conditions;
- E. Each patient using [drug name] is subject to certain monitoring. Append specified procedures to the REMS; or
- F. Each patient using [drug name] be enrolled in a registry. Append any enrollment forms and other related materials to the REMS Document.

D. Implementation System

If an Implementation System is included in the proposed REMS, include the following:

Describe the implementation system to monitor and evaluate implementation for, and work to improve implementation of, Elements to Assure Safe Use (B), (C), and (D), listed above.

E. Timetable for Submission of Assessments

For products approved under an NDA or BLA, specify the timetable for submission of assessments of the REMS. The timetable for submission of assessments shall be no less frequent than by 18 months, 3 years, and in the 7th year after the REMS is initially approved. You should specify the reporting interval (dates) that each assessment will cover and the planned date of submission to the FDA of the assessment. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. For example, the reporting interval covered by an assessment that is to be submitted by July 31st should conclude no earlier than June 1st.

Include the following paragraph in your REMS:

COMPANY will submit REMS Assessments to the FDA <<Insert schedule of assessments: at a minimum, by 18 months, by 3 years and in the 7th year from the date of initial approval of the REMS (DATE of Approval) >> To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. COMPANY will submit each assessment so that it will be received by the FDA on or before the due date.

Sections of the Old Document Template

- I. Goals
- II. REMS Elements
 - A. Medication Guide
 - B. Communication Plan
 - C. Elements to Assure Safe Use
 - A. Healthcare providers who prescribe [drug name] have particular training or experience, or are specially certified. Append any enrollment forms and relevant attestations/certifications to the REMS;
 - B. Pharmacies, practitioners, or healthcare settings that dispense [drug name] are specially certified. Append any enrollment forms and relevant attestations/certifications to the REMS;
 - C. [Drug name] may be dispensed to patients only in certain healthcare settings (e.g., hospitals);
 - D. [Drug name] may be dispensed to patients with documentation of safe-use conditions;
 - E. Each patient using [drug name] is subject to certain monitoring. Append specified procedures to the REMS; or
 - F. Each patient using [drug name] be enrolled in a registry. Append any enrollment forms and other related materials to the REMS Document.
 - D. Implementation System
 - E. Timetable for Submission of Assessments

DEVELOPMENT OF THE NEW REMS DOCUMENT TEMPLATE




Lack of Standardization



REMS requirements are described in a variety of ways and lack consistent terminology:

- Similar concepts often have different names
- Different concepts may have the same name
- REMS are often described using regulatory terms like "ETASU", "Communication Plan" and "Element A-F", which do not provide useful information about how REMS programs work

Stakeholder Feedback on REMS Requirements



- Requirements are not communicated in a clear and consistent manner
- Unclear who is responsible for implementing each REMS requirement
- Too much time spent trying to understand and comply with REMS
- Difficult to integrate REMS into existing health information systems and health care delivery processes

Purpose of the Revising the REMS Document



- Develop a method to share clear and consistent information about the REMS requirements
- Facilitate integrating REMS into the healthcare system
- Provide a better resource for industry for creating a REMS document
- Provide a foundation for developing best practices and continuous quality improvement



Efforts to Improve how REMS Requirements are Captured

To address stakeholder concerns, we have taken the following steps: 1.Characterized existing REMS by creating an inventory of REMS requirements and various ways they have been communicated across REMS programs

- 2.Created a new way of communicating REMS requirements called the REMS Participant Section
 - Standardized how REMS requirements are described and minimized unnecessary variations
 - Made REMS requirements more consistent, predictable and easier to understand

3.Received additional feedback from stakeholders through ongoing outreach efforts

4.Refined the new REMS document template



Additional Benefits of the Initiative

Enables information to be repurposed for REMS SPL submissions and REMS@FDA Website:

- REMS SPL
 - Once applicants start using the new REMS document template, creation of "REMS summaries" for the purpose of submitting REMS in SPL will no longer be necessary
- REMS@FDA Website
 - Website REMS Summary uses a similar approach to the new REMS document template. Once applicants start using the new template, the website REMS Summary can be automatically populated using the participant section of the REMS document



Guiding Organizational Principle

<u>Who</u> has to do what, when and with what



New Template & "4 W's" of REMS




"W"	Description	Examples
"Who"	The participant who must meet the REMS requirement	prescriber, dispenser, health care setting
"When"	A particular "stage" in the treatment or medication use process around which REMS activities needs to occur	certification, prescribing, dispensing, administration
"What"	a clinical or administrative activity that must be performed as part of the REMS	counseling a patient, completing an enrollment form, lab testing
"With What"	Approved REMS material with which the requirement is carried out	enrollment form, medication guide, educational pamphlet

OVERVIEW OF THE NEW REMS DOCUMENT TEMPLATE






New REMS Document Template



The Template is 19 Pages?!?!?



Substantially more instruction and standardized text to choose from





How to Use the Template

- Red Text = Instructions
- Black Text = Standardized template text
- Blue text = Name of REMS Material
- [Bracketed (blue or black) text] = Information that needs to be entered

How to Use the Template



- Formatting is standardized
 - -Margins
 - "narrow" setting (0.5" top, bottom, left, and right)
 - Font
 - Headers: Verdana 14 bold
 - Text: Verdana 10



How to Use the Template


- Retain what requirements apply, delete what requirements do not apply
- Requirements are not changing, how the requirements are organized has changed
- Use the standardized text
 - Covers the most commonly used requirements
 - Some REMS requirements have multiple versions of standardized text to describe the different ways the requirement can be carried out
 - The different versions of a requirement appear in black text, separated by the word "OR" in red text

Sections of the New REMS Document Template

- I. Administrative Information
- II. REMS Goals
- **III. REMS Requirements**
 - Section A: REMS Participant Requirements
 - Healthcare providers who prescribe must
 - Patients who are prescribed
 - Healthcare settings/prescribers/pharmacies that dispense must
 - Wholesalers that distribute must
 - Section B: REMS Applicant Requirements
 - Training
 - Communication
 - Operations
 - Compliance
- IV. REMS Assessment Timetable
- V. REMS Materials

Administrative Information







New Template

- I. Administrative Information
- II. REMS Goals
- III. REMS Requirements
 - Section A: REMS <u>Participant</u> Requirements
 - Healthcare providers who prescribe must
 - Patients who are prescribed
 - Healthcare settings/prescribers/pharmacies that dispense must
 - Wholesalers that distribute must
 - Section B: REMS <u>Applicant</u> Requirements
 - Training
 - Communication
 - Operations
 - Compliance
- IV. REMS Assessment Timetable
- V. **REMS** Materials



New Template

- I. Administrative Information
- II. REMS Goals
- **III. REMS Requirements**
 - Section A: REMS <u>Participant</u> Requirements
 - Healthcare providers who prescribe
 - Patients who are dispensed
 - Healthcare settings/prescribers/pharmacies that dispense
 - Wholesalers that distribute
 - Section B: REMS <u>Applicant</u> Requirements
 - Training
 - Communication
 - Operations
 - Compliance
- IV. REMS Assessment Timetable
- V. REMS Materials

REMS Requirements – Old Template

1. Healthcare providers who prescribe Welipax must be certified

- a. To become certified to prescribe Welipax, prescribers must:
 - i. Review the Prescribing Information for Welipax
 - ii. Review the Welipax REMS Education Program.
 - iii. Enroll in the Welipax REMS Program by completing the Welipax REMS Program Prescriber Enrollment Program.

b. As a condition of certification, prescribers must:

- i. Enroll each patient in the Welipax REMS Program by performing the following:
 - Prior to providing the first prescription, counsel the patient that holiday stress has occurred in patients treated with Welipax by informing the patient of the following:

Complete the Welipax REMS Program Patient-Prescriber Agreement Form for each patient. Submit the completed form to the Welipax REMS Program and store a copy in the patient's records.

- 3) Provide the patient with the Welipax REMS Program Patient Wallet Card.
- Inform the Welipax REMS Program if an enrolled patient has discontinued therapy or is no longer under your care.

c. FarmFa must:


- Ensure that prescribers who prescribe Welipax are certified in accordance with the requirements described above.
- Provide all the following mechanisms to complete the certification process for the Welipax REMS Program: online.

Loosely organized based on timing

REMS Requirements – New Template



FarmFa must ensure that health care providers, patients, pharmacies, and wholesalers/distributors comply with the following requirements:



Key Points - REMS Participant Requirements



- What to Include
 - Activities required by REMS participants to undertake
- What not to include
 - Activities that REMS participants learn about, understand, or acknowledge but do not agree to undertake
 - Activities that REMS participants do not need to complete in order to be able to use the drug
- If there are different requirements for different patient populations (e.g. pediatric), repeat this table for each population, and modify the header accordingly
- If there are different requirements for different types of health care settings, repeat this table for each type of health care setting (e.g., inpatient pharmacy vs outpatient pharmacy)
- Dedicated section for patients and wholesalers

New Template



- I. Administrative Information
- II. REMS Goals
- III. REMS Requirements
 - Section A: REMS *Participant* Requirements
 - Healthcare providers who prescribe
 - Patients who are dispensed
 - Healthcare settings/prescribers/pharmacies that dispense
 - Wholesalers that distribute

Section B: REMS <u>Applicant</u> Requirements

- Training
- Communication
- Operations
- Compliance
- IV. REMS Assessment Timetable
- V. **REMS** Materials

Applicant Requirements



• Old template

- "[Applicant] must..." appears in a variety of places
 - under each element (i.e., MG, CP, ETASU) as well as, if applicable, the Implementation System

New template

- All requirements pertaining to the Applicant are organized under "Section B - Applicant Requirements"
 - Training
 - Communication
 - Operations
 - Compliance

Communication Materials



- All materials related to communication are organized into one section
- In tabular format and includes standardized text

To inform healthcare providers about the REMS Program and the risks and safe use of Welipax, FarmFa must disseminate REMS communication materials according to the table below:

Target Audience	Communication Materials-& Dissemination Plans
All prescribers likely to prescribe Welipax	REMS Letter: Healthcare Provider REMS Letter with attachment: Fact Sheet
	 Mail within 30 calendar days of the date Welipax is first commercially distributed and again 6 months later.
	eMail within 30 calendar days of the date Welipax is first commercially distributed and again 6 months later.
	Make available via a link from the Welipax REMS Program Website.
	Disseminate through professional societies and request the content be provided to their members.
	Disseminate at Professional Meetings for 1 year from the date Welipax is first commercially distributed.



New Template

- I. Administrative Information
- II. REMS Goals
- **III. REMS Requirements**
 - Section A: REMS *Participant* Requirements
 - Healthcare providers who prescribe
 - Patients who are dispensed
 - Healthcare settings/prescribers/pharmacies that dispense
 - Wholesalers that distribute
 - Section B: REMS <u>Applicant</u> Requirements
 - Training
 - Communication
 - Operations
 - Compliance

IV. REMS Assessment Timetable

V. REMS Materials



New Template

- I. Administrative Information
- II. REMS Goals
- **III. REMS Requirements**
 - Section A: REMS *Participant* Requirements
 - Healthcare providers who prescribe
 - Patients who are dispensed
 - Healthcare settings/prescribers/pharmacies that dispense
 - Wholesalers that distribute
 - Section B: REMS Applicant Requirements
 - Training
 - Communication
 - Operations
 - Compliance
- IV. REMS Assessment Timetable

V. **REMS** Materials

REMS Materials



Old template

- Materials are listed under each section they correspond to

New template

- Hyperlink when they appear in the text of the REMS Document
- Organized by type of material and target audience
- Complete list of ALL the REMS materials appear in their own section at the end of the REMS Document

V. REMS Materials

The following materials are part of the Welipax REMS and are appended:

Enrollment Forms

Prescriber

1. Prescriber Enrollment Form

Patient

2. Patient-Prescriber Agreement Form Pharmacy

3. Pharmacy Enrollment Form

Training and Educational Materials

Prescriber

4. Prescriber Education Program Patient

5. Patient Wallet Card

Communication Materials

- 6. Healthcare Provider REMS Letter
- 7. Fact Sheet

Other Materials

8. REMS Program website



SUBMITTING A REMS DOCUMENT

Submitting a REMS Document



- If you plan to submit a new REMS....
 - Expect all REMS submissions in the new format
- If you have an approved REMS....
 - Do not expect submission solely to convert to the new format
 - Recommend submitting with other modifications
 - We can assist in converting to the new format

• Provide feedback!

 We encourage you to provide feedback on the new REMS document template and the accompanying draft guidance

The new REMS document template and instructions for use can be found in the draft guidance for industry *Format and Content of a REMS Document,* available at: <u>https://www.fda.gov/AboutFDA/Transparency/Basics/ucm325201.htm</u>.

Agenda



- 1. Introduction & Background (Aaron Sherman)
- 2. The new REMS document template (Gita Toyserkani and Suzanne Robottom)
- 3. REMS@FDA website update (Amy Ramanadham)
- 4. REMS SPL update (Adam Kroetsch)



CSV

Print

Excel

REMS@FDA



Contact Us | REMS Basics | 🔤 Get REMS Email Alerts | Reports & Data Files

The Food and Drug Administration Amendments Act of 2007 gave FDA the authority to require a Risk Evaluation and Mitigation Strategy (REMS) from manufacturers to ensure that the benefits of a drug or biological product outweigh its risks.

The table below provides links to currently approved individual and shared system REMS.

Information on historical and released REMS is available in downloadable: data files.

Filter by Keyword (e.g. REMS name, active ingredient, element)

Name	•	REMS Approved	Last Updated [‡]	MedGuide (MG)*	Comm. Plan (CP)	ETASU 🛊	Imp. System (IS)
Adasuve (loxapine), aerosol, powder NDA #022549		12/21/2012	10/10/2017			ETASU	IS
Addyi (flibanserin), tablet NDA #022526		08/18/2015	06/16/2017			ETASU	IS
Adempas (riociguat), tablet, film coated NDA #204819		10/08/2013	01/17/2017	MG		ETASU	IS



Objectives



- Understand how the website is organized to meet the needs of different users.
- Identify enhancements to the website made based on user feedback.
- Recognize the website's features, including displaying the "4 W's"

Brief history of REMS@FDA



- In 2008, launched website to improve transparency.¹
- In 2015, launched website which is a centralized, standardized, reliable, and user-friendly repository of information about REMS that can:
 - Help participants understand and comply with REMS requirements.
 - Minimize the confusion associated with complying with multiple REMS programs.
 - Provide participants, researchers, and others with access to convenient, up-to-date and comprehensive REMS info
- In 2017, made enhancements to website based on users feedback.

The website must meet the needs of a wide range of users



Who uses the website?



- Patients
- Healthcare providers
 - Prescribers
 - Pharmacists
 - Nurses
 - Health system pharmacists
- Distributors
- Drug data vendors
- Academics/researchers
- Industry
- FDA



What do users want?

Website Use Case	Key User Questions
Patient or healthcare provider wants to learn about a specific REMS.	Does the product I use have a REMS? What do I have to do to comply with the REMS?
Health system pharmacist wants to implement one or more REMS in their organization.	What do all of the participants have to do in this REMS? How does this REMS compare to other REMS that our organization has implemented in the past? Do we need to set up new systems or processes to implement this REMS?
Researcher wants to study FDA's use of REMS	How many REMS are there? What elements do they use, and what do they require of participants? How has that changed over time?
Drug data vendor wants to incorporate data about REMS into their database.	How can we download and extract all of the information found on the REMS website?



How the site is organized?

Contact Us REMS Basics Get REMS Email Alerts The Food and Drug Administration Amendments Act of 20 ensure that the benefits of a drug or biological product out The table below provides links to currently approved indivi Information on historical and released REMS is available in Filter by Keyword (e.g. REMS name, active ingredient.	107 gave FDA the authorit weigh its risks. idual and shared system f n downloadable: data file	REMS.	Evaluation and Mitigation Strategy (RE	MS) from ma	CSV Print	Subc KDA # KBA #	REM Contect	Sub MAA	Constant Con		
NSILL Adasuve (loxapine), aerosol, powder NDA #022549 Addyi (fibanserin), tablet NDA #022526 A propas (riocigual), tablet, film c. uted	REMS + 12/21/2012 + 08/18/2015 +	Last Updated + 10/10/2017 06/16/2017 01/17/2017	MedGuide + Comm. Plan + (MG)*	ETASU \$ ETASU ETASU ETASU	Imp. System ϕ (IS) IS IS IS		NDA 403		(Ioxapine) SEFDA Iox St (RIMS Bases (2) Or REMI Grant Warts Report tretinoin IPLEDGE Iox space fiel/2017 Included Cools Continuous Internet What medicines are included in the REM	h Update history	
									Assesses (connections) (PE and PE at Delyters) (of an Delyter of) Annexes (connections) (PE and PE at Delyters) (of an Delyter of) Annexes (connections) (PE and PE at Delyters) (of an Delyter of Connections) (PE and PE at Delyters) (of an Delyter of Connections) (PE and PE at Delyters) (of an Delyter of Connections) (PE and PE at Delyters) (of an Delyter of Connections) (PE and PE at Delyters) (of an Delyter of Connections) (PE and PE at Delyters) (of an Delyter of Connections) (PE and PE at Delyters) (of an Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE and PE at Delyters) (of a set Delyter of Connections) (PE at Delyter of Connections) (of a set	Application Revides Mills 02105 ANDA 02505 ANDA 02505 ANDA 02505 ANDA 02505 ANDA 02505 ANDA 02505 ANDA 02505	Application problem Gate Reading Parts Inc. Minical Parts Inc. Minical Parts Inc. Try a Personne Unc. Minical Personne Unc. Minical Personne Unc.

REMS-specific pages

Homepage

Excel CSY Pret

Added to REMS

45/25/2013

34/22/2018

10/72/2010

10/22/2018

INCOMPACT.



How the site is organized?

REMS@FDA						REMS#FDA
Contact Us REMS Basics G Get REM Email Al						Contact Us REMS Basks Oct REMS Evall Alerts Reports & Data Pies
The Food and Drug Administration Amenda onto Act of ensure that the benefits of a drug or biologics, produc		nty to require a Risk	Evaluation and Mitiga	ation Strategy (REMS) from manu	facturers to	REMS Reports
he table below provides links to currently approved	idual and shared such	meMS.				+ REMI count
nformation on historical and released REMS is availa	ible in downloadable: data file	69.				Durriently, there are 76 REM3. = 44 (19%) wonder "elements to assure safe user /ETASU) /REMS with ETASU typically require initiation or health care settings to become certifield and to prescribing and to
Filter by Keyword (e.g. REMS name, active ingred	Sent, element)			Excel	CSV Print	participate in additional 42:05 activities, such as transing paravit counseling, and monitoring.
		11430 <u>-</u>			CONTRACTOR OF THE	 12 (17%) instacte unity a "communication plan" REMS element which is informational in nature. These communication plans are typically composed of letters, websites, and fact shee describing the specific sativity mass identified in the 48(MS).
Name	+ REMS Approved	Updated \$	MedGuide (MG)*	Comm. Plan ‡ ETASU ‡ (CP)	Imp. System (IS)	 18 (24%) mixeds only like "reststabling usite" REMS element. Even probably that do not nave "modication guide" REMS elements may have metication guides as pert of their latering.
Adasuve (loxapine), aerosol, powder NDA #022540	12/21/2012	10/10/2017		ETASU	15	Released REMS This report this offernation for released REMS-groups where REMS program is no larger in effect; including the late the REMS was approved, date the REMS was missionil and
Addyi (filbanserin), tablet	08/18/2015	06/16/2017		ETASU	IS	the REVO is a strated dystem.
NDA #022528				072777	10.1	REMS Data Files and Historic REMS Information
Adempas (riocigual), tablet, film coated	10/08/2013	01/17/2017	MG	ETASU	IS	The information presented on this sedepte, as well an instruct information about REMS and their modifications, is compared in the REMS Outp Piles book All Idea before include information
NDA #204819					10.11.0	about current REMS as well as REMS that are no longer in place.


Homepage

Reports & Data Files page 55

What you can find on REMS@FDA

- A searchable and sortable table of current REMS programs on the homepage.
- On REMS specific-pages:
 - A listing of what participants need to do to quickly orient prescribers, patients and pharmacists (i.e. the four 'W's)
 - Links to relevant information: labeling, Drugs@FDA, the application holder's REMS website, and REMS materials.
- More detailed REMS data in downloadable CSV format on the Reports & Data Files page.
- Uses an adaptive design to view from a mobile device.








Contact Us REMS Basics G Get REMS Email Alerts Rep The Food and Drug Administration Amendments Act of 2007 g ensure that the benefits of a drug or biological product outweig	ave FDA the author hits risks.		Evaluation and Miligati	on Strategy (REMS) from manul	acturers to	
The table below provides links to currently approved individual information on historical and released REMS is available in dow					cou [044]	
Filter by Keyword (e.g. REMS name, active ingredient, elen	REMS	Last .	MedGurue	Comm Plan	CSV Print	
Name	Approved	Updated +	(MG)* *	(CF)	(15)	Search for REMS using
Adasuve (loxapine), aerosol, powder NDA #022540	12/21/2012	10/10/2017		ETASU	15	the REMS name, active
Addyi (fibanserin), tablet NDA #022528	08/18/2015	06/16/2017		ETASU	IS	ingredient or element.
Adempas (nocigual), tablet, film coated NDA #204819	10/08/2013	01/17/2017	MG	ETASU	IS	









A CONTRACTOR OF			-			
REMS@FDA Contact Us REMS Basics Get REMS Email Alerts Rep The Food and Drug Administration Amendments Act of 2007 ga ensure that the benefits of a drug or biological product outweight	we FDA the authorit	y to require a Risk E	valuation and Mitig	Search e shared s	-	e 2,
The table below provides links to currently approved individual a Information on historical and released REMS is available in dow	-					
shared system					Excel	CSV
Name 🔺	REMS Approved	Last Updated [♦]	MedGuide (MG)* ♦	Comm. Plan (CP) ♦	ETASU	lmp. Syst (IS)
Alosetron Shared System REMS	11/22/2016	11/22/2016			ETASU	
Buprenorphine Transmucosal Products for Opioid Dependence (BTOD) Shared System REMS	02/22/2013	05/23/2017	MG		ETASU	IS
Clozapine Shared System REMS	09/15/2015	09/15/2015			ETASU	IS

































This report lists information for released REMS (products whose REMS program is no longer in effect) including the date the REMS was approved, date the REMS was

released, and if the REMS is a shared system

Contact Us REMS Basics Cot REMS Email Alerts Reports & Data Files REMS Reports	
REMS count Currently, there are 75 REM8 = 44 (59%) include "elements to assure safe use" (ETASU). REMS with ETASU typically require clinicians or health care settings to become certified prior to prescribing and to participate in additional REMS activities, such as fraining, patient counseling, and monitoring.	Current count of REMS
• 13 [17%] include only a "communication plan" REMS element which is informational in nature. These communication plans are typically composed of letters, websites, and fact sheets describing the specific safety risks identified in the REMS.	by element
a 18 [24%] include only the "medication guide" REMS element. Even products that do not have "medication guide" REMS elements may have medication guides as part of their tabeling.	



		Coloris, Napartina Sala Fran					Report of released REMS
	А	В	С	D	E	F	1
	REMSID	REMS_Name	Application_Nu	REMS	Date REMS	Date REMS	
			mber	Shared	approved	released	
1				System			
2							
3	369	Bupropion (ANDA 091520)	091520;	No	6/9/2011		-
4	66	Victoza	022341;	No	1/25/2010		
5	370	Bupropion (ANDA 077475)	077475;	No	6/25/2010		-
6	371	Bupropion (ANDA 079094)	079094;	No	4/27/2010	6/30/2017	7
7	372	Bupropion (ANDA 075914)	075914;	No	5/13/2010	6/30/2017	7
8	65	Vibativ	022110; 022407;	No	9/11/2009	5/24/2017	7
9	39	Nulojix	125288;	No	6/15/2011	5/9/2017	7
10	73	Zyban	020711;	No	2/26/2010	5/4/2017	7
11	19	Forteo	021318;	No	7/22/2009	4/28/2017	7
12	6	Aranesp	103951;	No	2/16/2010	4/13/2017	7
13	16	Epogen / Procrit	103234;	No	2/16/2010	4/13/2017	7
14	320	Symlin	021332;	No	6/27/2014	3/8/2017	7
15	50	Stelara	125261;	No	9/25/2009	2/15/2017	7
16	12	Chantix	021928;	No	10/19/2009	12/16/2016	5
17	22	Gilenya	022527;	No	9/21/2010	11/29/2016	5



REMS Data Files and Historic REMS Information	
The information presented on this website; as well as historic information about REMS and their modifications, is compiled in the REMS Data Files below. All files below include information about current REMS as well as REMS that are no longer in place.	
Download REMS data (Includes Released REMS) (REMS.csv) This file presents a list of all approved REMS, including REMS that are no longer in place.	Downloadable REMS
Download REMS Versions data (REMS_Versions.csv) This file includes details on all modifications and revisions to each REMS program, including information on no-longer-current revisions and modifications.	data in CSV format
 Download REMS Products data (REMS_Products.csv) This file includes data on all of the drugs that have ever been part of a REMS program, including information on products that are no longer marketed and/or no longer subject to a REMS. 	
Download REMS Materials data (REMS_Materials.csv) This file includes a list of all materials that have been a part of the REMS, and provides links to REMS materials stored at FDA's website, when available. This includes materials that are no longer part of a current REMS	
Data Description	Detailed description of
The data available on this page is organized into four tables, each or which can be violated on its own or in combination with other tables as part of a relational database. The entity-relationship diagram below shows the fields in each of these tables and how they should be linked together to norm exemptionship REMS database.	Detailed description of
REMS@FDA: Entity-Relationship Diagram	the data contained in
	downloadable REMS

data



							ſ	REMS_v	ersion f	ile
	-	NUMBER OF COMPANY					-1			
F	A	В	с	D	E	F	G	Н		1
	REMSID	REMS_Name	VersionI	Version_Da	_	Moved t			Elements	Implem
		_	D	te –	_Flag				_to_Assu	
						System			re_Safe_	
1						Flag			Use_Flag	ag
244	16	Epogen / Procrit	50	2/16/2010	0	0	1	1	1	
245		Epogen / Procrit	51	6/24/2011	0	0	1	1	1	
246	16	Epogen / Procrit	52	5/31/2012	0	0	1	1	1	
247	16	Epogen / Procrit	53	3/27/2013	0	0	1	1	1	
248	16	Epogen / Procrit	326	12/31/2013	0	0	0	0	1	
	16	Epogen / Procrit	976	4/13/2017	4	0	0	0	0	

Next steps



- A series of enhancements made the REMS website responds to user feedback.
- The new REMS document template (REMS Participant Requirements Section), organized by the "4 W's", will be displayed on REMS-specific pages.
- Plan to use REMS SPL submissions to help maintain the website

www.fda.gov/rems

Agenda



- 1. Introduction & Background (Aaron Sherman)
- 2. The new REMS document template (Gita Toyserkani and Suzanne Robottom)
- 3. **REMS@FDA** website update (Amy Ramanadham)
- 4. REMS SPL update (Adam Kroetsch)

What is SPL?



SPL is a data standard for capturing information about drug products:

- SPL stands for "Structured Product Labeling" but covers product information beyond labeling
- SPL is developed and maintained by a Standards Development Organization called Health Level Seven International (HL7)

Proposal to capture REMS in SPL format was identified by stakeholders (in particular, the National Council for Prescription Drug Programs, NCPDP) and was adopted in 2014 as a "priority project" towards REMS Standardization.



What is SPL not?

REMS SPL is not currently used for the exchange of patient or healthcare provider-specific information

- For example, prescribers cannot use SPL to enroll in a REMS, prescribe drugs, or monitor patients.
- A related effort, the REMS Platform Standards Initiative, is designed to develop standards to exchange this type of information.



REMS SPL starts with the official "REMS Document"

REMS Document

11	APPENDIX: REMS DOCUMENT TEMPLATE
\$7	Risk Evaluation and Mitigation Strategy (REMS) Document
	[Drug/Class Name (Generic Name)] REMS Program
89 -	
90 90 91 92	The REMS document formulate has free sections: 11 Administrative Information (1), REMS locals (11) REMS Requirements (10) REMS assessment Remetable VI REMS Humanian Depending on the REMS requirements, the REMS document will include sections and test, a applicable.
93	Template Key
94	Red Test - Instructions
95.	Black Text + Standardined text (See text with Systemick = Name of RENS Material's)
98	(Bracketed (Inia or black) text) - Information that needs to be arrived
97	a di kana ku kana kana ku ku ku
98	I. Administrative Information
299	Application Number(s): NDA/BLA (application number(s)) Use this only for single-applicant.
00	Roman Holder: Lappicant name! Use this unit for single-applicant ROM
62	Initial (Shared System) REMS Approval: [MM/VYYY]
63	Most Recent REMS Update: (MM/YYYY) Enter the date of the most recent REMS Revision or
04	approved Modification. If there are no coldates since the initial approval, delete the text.
Q5	
06	II. REMS Goal(s)
07	This section describes the overall, safety-related health sutcome that the KENE is designed
108	In actions (e.g., willights the risk of a particular partous adverse event) and the
109	intermediate, measurable (dijectives. In many cases, it is not people to measure a risk mitigation goal directly: therefore, it is important to include one or more intermediate.
11	manurable objectives that, if advanced, indicate that the program is meeting its poal til.
12	
13	[Overall REHS goal] I. (REHS objective)
24	 (PEPS objective) (Other REPS phractives, as readed)
18	al france and a failure and an ensembly
11	III. REMS Requirements
18	This section describes the REHS requirements for the applicant, including requirements that
19	the applicant must undertake directly and requirements that the applicant must ensure that
20	88465 perfoquents undertake. REPES participants can incluite preventiers, depensers, health
21	care settings, patients (or their guardians), and whensaleny distributors.
44	
148	

REMS Materials





What REMS SPL Looks Like

1. Healthcare Providers who prescribe [drug	/class name] must:
	1. Be able to [clinical activity to be performed].
	2. Review the drug's Prescribing Information.
To have a set for the surrouth	3. Review the following: [List of Prescriber Educational Material(s)].
To become certified to prescribe	4. Receive training provided by [entity providing the training, e.g. the applicant, a CE provider].
	5. Successfully complete the [Knowledge Assessment Form] and submit it to the REMS Program.
	6. Enroll in the REMS by completing the [Enrollment Form] and submitting it to the REMS Program.
	7. Counsel the patient on [topic]
	OR
	Counsel the patient using [REMS material].
	OR
	Counsel the patient on [topic] using [REMS material].
	Provide the patient with the [REMS Material].
	Assess the patient's [condition(s) or health status(es)].
	OR
	Assess the patient's [condition(s) or health status(es)]. Document and submit the results to the REMS Program using [REMS Material(s)].
	OR
	Assess the patient's [condition or health status] by [list of lab test(s) or monitoring].
	OR
	Assess the patient's [condition(s) or health status(es)] by [list of lab test(s) or monitoring]. Document and submit the results to the REMS Program using [REMS Material(s)].
Before treatment initiation (first dose)	10. Complete the [Patient Form]. Provide a completed copy of the form to the patient.
	OR
	Complete the [Patient Form]. Retain a completed copy in the patient's record.
	OR
	Complete the [Patient Form]. Provide a completed copy of the form to the patient and retain a copy in the patient's
	record.
	11. Enroll the patient by completing and submitting the [Patient Enrollment Form] to the REMS program.



What REMS SPL Really Looks Like

```
<effectiveTime value="20141014"/>
<component>
   <section ID="Lef1212ba-f0f9-481f-a18d-e4bd24673b09">
       <id root="56a78ca3-34d9-4979-9dd6-002a98a43a3a"/>
       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
       <title>1. Healthcare Providers who prescribe [drug/class name] must:</title>
       <text>
           <caption/>
               To become certified to prescribe
                       <content ID="R001">1. Be able to [clinical activity to be performed].</content>
                           \langle br/ \rangle
                           <content ID="R002">2.
                                                  Review the drug's Prescribing Information.</content>
                           \langle br/ \rangle
                           <content ID="R003">3.
                                                  Review the following: [List of Prescriber Educational Material(s)].</content>
                           \langle br/ \rangle
                           <content ID="R004">4.
                                                  Receive training provided by [entity providing the training, e.g. the applicant
                           \langle br/ \rangle
                           <content ID="R005">5.
                                                  Successfully complete the [Knowledge Assessment Form] and submit it to the REMS
                           \langle br/ \rangle
                           <content ID="R006">6. Enroll in the REMS by completing the [Enrollment Form] and submitting it to the
                       \langle tr \rangle
                   \langle tr \rangle
                       Before treatment initiation (first dose)
```



Why SPL?

- 1. Presents information about REMS in a consistent "4 W's format".
- 2. Makes REMS information more accessible.
- 3. Helps integrate REMS into the care process.



Data Element	Description	Examples
Stakeholder ("Who")	The party that must meet the REMS requirement	prescriber, dispenser, health care setting
Protocol ("When")	A particular "stage" in the treatment process around which REMS activities may occur	certification, prescribing, dispensing, administration
Requirement ("What")	A clinical or administrative activity that must be performed as part of the REMS	counseling a patient, completing an enrollment form, lab testing
Material reference ("With What")	Reference to approved REMS material with which the requirement is carried out	enrollment form, medication guide, educational pamphlet



In SPL, old format REMS Documents are transformed into REMS Summaries

REMS Document Text

To become certified, each prescriber must activate registration, by completing the Prescriber Enrollment Form, via the iPLEDGE website or the automated phone system.

The healthcare provider completes the Healthcare Provider Enrollment Form.

To become certified, each prescriber must complete the Prescriber Enrollment Form

REMS Summaries

		1. Designate an as	thorized representative to carry out the certification
	3. Pharm	acies that dispense	Drug X:
Tobe	_	1 Desire	ate an authorized concentration to carry out the costilication
dape		3. Pharmacies that	t dispense Drug X:
	To be all dispense		 Designate an authorized representative to carry out the certification process on behalf of the phannacy. Have the authorized representative review the educational materials for
Befor Drug		To be able to dispense Drug X	dispensers, including Program Overview 3. Train all relevant staff involved in the dispensing of Drug X using the Program Overview.
Ougo	Before d Drug X		Establish processes and procedures to verify dispensing to certified affision centers only 5. Eurol in the REIMS by completing and submitting the Pharmacy Earolinear Form.
_	Ongoing	Before dispensing Drug X	 Obtain Prescription Ordering Forma from the Drug X REMS Program 7. Obtain authorization to dispense by calling the Drug X REMS Program
		Ougoing	 Re-enroll is the Drug X REMS program every 2 years. Do not distribute, transfer, loan, or sell product except to certified despinares. Cooperate with andire carried out by the sponser to ensure that all processes and procedures are in place and are bring followed.

4 W's in REMS SPL



REMS SPL presents the "4 W's" for *all* REMS in tabular format:

1. Healthcare Providers who prescribe drug X must:

To become certified to prescribe	Review the drug's Prescribing Information. Enroll in the REMS by completing the Drug X REMS Enrollment Form and submitting it to the REMS Program.
Before treatment initiation (first dose)	Counsel the patient using Drug X REMS Counseling Material. Assess the patient's [condition(s) or health status(es)].

REMS Summaries are not necessary for REMS Documents that follow the new REMS document template

Comparison: Old vs New Template



Old Template	New Template
Header	REMS Administrative Information
REMS Goals	REMS Goals
REMS Elements Medication Guide REMS Communication Plan REMS Elements to Assure Safe Use	REMS Requirements REMS Participant Requirements REMS Sponsor Requirements
REMS Implementation System REMS Assessment Timetable*	REMS Assessment Timetable
REMS Summary	REMS Material
REMS Material	




Why SPL?

- 1. Presents information about REMS in a consistent "4 W's format".
- 2. Makes REMS information more accessible.
- 3. Helps integrate REMS into the care process.



REMS SPL information is shared across the healthcare system

SPL data is transmitted from the sponsor to patients, healthcare providers, and the public





FDA will be using REMS SPL for its own REMS website

Filter by Keyword (e.g. REMS name, active ingre	edient, elen	nent)				Excel	CSV Print
Name		REMS Approved	Last Updated [♦]	MedGuide (MG)* ●	Comm. Plan (CP) ∳	ETASU 👙	Imp. System (IS)
Adasuve (loxapine), aerosol, powder NDA #022549		12/21/2012	10/10/2017			ETASU	IS
Addyi (flibanserin), tablet NDA #022526		08/18/2015	06/16/2017			ETASU	IS
Adempas (<i>riociguat</i>), tablet, film coated NDA #204819		10/08/2013	01/17/2017	MG		ETASU	IS
Drug Name, NDA number, dosage form		Approval Date		REMS Elements			



Why SPL?

- 1. Presents information about REMS in a consistent "4 W's format".
- 2. Makes REMS information more accessible.
- 3. Helps integrate REMS into the care process.



In REMS SPL, "4 W's" are mapped to standardized data elements

4W's: REMS Summary / REMS Participant Requirements

Standardized Data Elements

Pharmacies t	that dispense Drug 3			
3. Phan	process on behalt	vized concessuative orging: the educational materials for	Stakeholder	Prescribers
per To be al	3. Pharmacies the	note an authorized representative to carry out the certification on behalf of the pharmacy.	 Protocol	To be able to prescribe
ign Before o	To be able to dispense Drug X	 Designate an authorized representative to carry out the certification process on behalf of the pharmacy. Have the authorized representative review the educational materials for dispensers, including: Program Overview Train all celevant stuff involved in the dispensing of Drug X using the Program Overview. 	Requirement	Enroll in REMS
Drug X Ougoing	·	4 Establish processes and procedures to verify dispenning to certified infusion centers only. 5 Enroll in the REMS by completing and submitting the Pharmacy Enrollment Form.		
	Before dispensing Drug X	 Obtain Prescription Ordering Forms from the Drug X REMS Program. Obtain authorization to dispense by calling the Drug X REMS Program. 		
	Ougoing	 Re-enroll in the Drug X REMS program every 2 years. Do not distribute, transfer, loan, or sell product except to certified disponsers. Cooperate with audits carried out by the sponsor to ensure that all processes and proceedness are in class and are being followed. 		

Data elements allow REMS to be integrated into health IT systems

<stakeholder>

1. Healthcare Providers who prescribe drug X must:

To become certified to prescribe		 Review the drug's Prescribing Information. Enroll in the REMS by completing the Drug X REMS Enrollment Form and submitting it to the REMS Program. 				
Before treatment initiation (first dose)		Counsel the patient using Drug X REMS Counseling Material. Assess the patient's [condition(s) or health status(es)].				
<protocol></protocol>		<requirement></requirement>	<document Reference></document 			




Illustrative Diagram: Animation

REMS Document Text

REMS Summaries

Standardized Data Elements






Illustrative Diagram: New Template

REMS Document Text

Standardized Data Elements



	Stakeholder	Prescribers
	Protocol	To be able to prescribe
	Requirement	Enroll in REMS

Bolice-During After	Activity	Realesbolder	Requirement	Dumment
hefere	al activity	dapeure	languist authorited representative	
lefue	al assess	daponet	Harn representative review adaptational materials	Propaga Division
befiere	slame.	Autom	The staff	Pages Owner-
lefaci	al annes	\$sprover	Emplois processes and providents to really only one conditions	
tefwe:	states	Approx	Devid a MDVA	Platury Earland Feb.
befase	-Separate g	Aspenne	official Approximity instantization."	
every 2 years through	dependent	Aspenne	Rend + MDM	
turng	deputying	&spense:	source depending only in certified previder.	
dang	dependent	Aspenne	Company with public	



The <stakeholder> Data Element uses a standard terminology to describe the role of the participant in the REMS:

- Prescriber
- Dispenser
- Patient
- Distributor
- Other Healthcare Providers (e.g., nurses who treat patients on the drug)



The <protocol> Data Element uses a standard terminology to describe the steps in the REMS and medication use process, such as:

- REMS Certification
- Treatment Initiation
- Dispensing
- Discontinuation

These terms are combined with "modifiers" to specify when a requirement needs to happen: e.g., "before REMS Certification", "after Treatment Initiation", "one week after Dispensing", etc.



The <requirement> Data Element uses a standard terminology to describe the clinical or administrative activities that stakeholders need to carry out in the REMS, such as:

- Enroll in the REMS
- Counsel patient
- Review Prescribing Information
- Get lab test or monitoring




The <documentReference> Data Element identifies the material used to carry out the REMS activity. In general, there are three types of "materials" that may be referenced in an SPL document:

- A REMS material (e.g., a form or educational material) – typically attached as a PDF
- A website, referenced as a URL
- An electronic data standard
 - Currently NCPDP's Telecommunications Standard is the only standard available, but more will be added in the future as needed.



Example of codified REMS within SPL






Codified REMS SPL information can be displayed in many different ways

Before/During/After	Activity	Stakeholder	Requirement	Document
before	all activity	dispenser	designate authorized representative	
before	all activity	dispenser	Have representative review educational materials	Program Overview
before	all activity	dispenser	train staff	Program Overview
before	all activity	dispenser	Establish processes and procedures to verify safe use conditions	
before	all activity	dispenser	Enroll in REMS	Pharmacy Enrollment Form
before	dispensing	dispenser	obtain dispensing authorization	
every 2 years during	dispensing	dispenser	Enroll in REMS	
during	dispensing	dispenser	ensure dispensing only to certified provider	
during	dispensing	dispenser	Cooperate with audits	

Use of REMS SPL in the Healthcare System





*For each drug handled through KP-SF; a 5OP is developed to define processes. This SOP also supports the development of an 5PUMS module for the drug and can be used for decentralized clinical monitoring services coordinated with the internal SP. This table throws the possible dements of the SOP. EHR=electronic health incompting services coordinated with the internal SP. This table throws the possible dements of the SOP. EHR=electronic health incompting through the internal SP. This table advects the possible dements of the SOP.

talty pharmacy, SPIMS - Specialty Pharmacy Information Management System, TTY - text telephone device.

Structured REMS data in a format like SPL can help integrate REMS into the healthcare system and ensure stakeholder awareness of and compliance with REMS.

Source: Journal of Managed Care Pharmacy.

http://www.amcp.org/JMCP/2013/May/16 524/1033.html

Use of SPL in the Healthcare System Prescriber Example



Scenario: A doctor is about to start a patient on a drug that has a REMS. The prescriber does not realize that the drug has a REMS. Fortunately, the prescriber's EHR contains SPL data.

- Using the <stakeholder> data element, the EHR notifies the prescriber that they have a role to play in the REMS.
- Using the < protocol> and <requirement> data elements, the EHR notifies the prescriber that there are several steps they have to take when initiating therapy with the patient, including providing the patient with counseling materials.
- Using the <documentReference> data element, the EHR presents a copy of the counseling material to the prescriber to print and give to the patient.

Use of SPL in the Healthcare System Dispenser Example



Scenario: A pharmacist is about to fill a prescription for a drug with a REMS. The pharmacist is aware that a REMS exists for the drug, but is not aware that the REMS has recently changed. Fortunately, the pharmacist's pharmacy system contains SPL data.

- Using the <protocol> and <requirement> data elements, the pharmacy system notifies the pharmacist that they must now confirm that a specific lab test result is on file before dispensing the drug.
- Using the <documentReference> data element, the pharmacy system learns that the lab test results can be requested electronically.
- Thanks to the "trigger" provided by SPL, the pharmacy system can now, using a different data standard, check with the REMS program to determine whether there is a negative lab test on file.

Next Steps



- Sponsors are now able to submit their REMS in SPL format
- Once REMS SPL files are approved, they will be made available on DailyMed
- We have issued a draft guidance under FD&C 745A(a) that would require REMS submissions in SPL format
 - We are now soliciting comments on the draft guidance, which will be considered as we develop a final guidance. Comments are due
 - Electronic submission requirements take effect 2 years from the publishing of a final guidance.
 - We will continue to have opportunities for stakeholder feedback prior to issuing final guidance.



Acknowledgments

- FDA Colleagues: CDER and Office of the Commissioner
- National Library of Medicine
- National Cancer Institute: Enterprise Vocabulary Services
- Pilot Participants and Applicants

Conclusion



- The REMS Integration Initiative was launched in 2011 to evaluate and improve the implementation of REMS authorities, and to reduce the associated burden
- It ended in October 2017 after:
 - Implementation of the 4 'W's REMS document template to standardize how REMS requirements are described
 - Creation of the REMS@FDA website for easy access to individual and program-wide REMS information
 - Incorporation of REMS into SPL format for *integration* with existing healthcare systems
 - Publishing 5 guidances and 3 reports to establish and discuss best practices in REMS implementation
- Efforts continue to evaluate and improve REMS
 - REMS Platform Standards Initiative

For more information...




- For more information the REMS Integration Initiative, including access to guidances and reports published, please visit the initiative's <u>website</u>
- The new REMS document template and associated guidance can be found <u>here</u>
- For instructions on creating REMS SPL documents, consult the SPL implementation guide, available <u>here</u>
- If you have questions, please contact the DRISK Policy Team at <u>REMS@fda.hhs.gov</u>
- The **REMS@FDA** website

Resources



Click for:

- Email questions to: <u>REMS@fda.hhs.gov</u>
- <u>REMS Integration Initiative website</u>
- <u>REMS Overview</u>
- FDA SPL Website
- REMS@FDA
- PDF of today's slides



Open Q&A begins shortly – type in your questions now.

Click Here for Evaluation and Certificate

Learn about other resources from CDER Small Business & Industry Assistance: <u>Visit Our Website!</u>